Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REIC gene therapy - Momotaro-Gene

Next Previous
Drug Profile

REIC gene therapy - Momotaro-Gene

Alternative Names: Ad5-SGE-REIC/Dkk-3; DKK3 gene therapy - Momotaro-Gene; MTG-201; REIC/Dkk-3 gene therapy

Latest Information Update: 22 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Momotaro-Gene
  • Developer Icahn School of Medicine at Mount Sinai; Kyorin Pharmaceutical; Momotaro-Gene
  • Class Antineoplastics; Cancer vaccines; Gene therapies
  • Mechanism of Action Apoptosis stimulants; DKK3 expression modulators; Gene transference; Tumour suppressor gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant-mesothelioma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant-mesothelioma
  • Phase I/II Prostate cancer
  • No development reported Liver cancer

Most Recent Events

  • 22 Jul 2022 REIC gene therapy is still in phase II trial for Malignant mesothelioma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intratumoural) (NCT04013334)
  • 22 Jul 2022 No development reported - Phase-II for Mesothelioma in Japan (Intratumoural)
  • 16 Jun 2022 Momotaro-Gene completes enrolment in its phase II trial for Malignant mesothelioma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Intratumoural) (NCT04013334)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top